Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,501–1,600 of 2,656
Lin, D. S., Lo, H.-Y., Yang, C., & Wu, C. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00760-x · Cited by 3
Hayes, A. G., Pearson, O. R., Marathe, C. S., & Jesudason, D. R. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.06.1019 · Cited by 2
Driendl, S., Stadler, S., Baumert, M., Stark, K. J., Heid, I. M., Pěč, J., Zeman, F., Preiss, A., Böger, C. A., Bergler, T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02918-y · Cited by 2
“The endpoint of kidney failure as defined in the present study, is a widely accepted endpoint in large studies [35, 36], and only needs blood samples to determine eGFR in addition to the clinical information.”
To screen or not to screen: why universal CKD testing is not a goer!
Wong, G., & van Zwieten, A. (2025) · Kidney International · doi:10.1016/j.kint.2025.05.040 · Cited by 2
Obesity-related glomerulopathy: a lesser known complication of obesity
Sharma, S., Sharma, A., Kapoor, N., Sharma, N., Saravanan, P., & Kalra, S. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000930 · Cited by 4
Malijan, G. M., Chapman, D., Moffat, S., Sardell, R. J., Staplin, N., Landray, M., Baigent, C., Shlipak, M. G., Haynes, R., Ix, J. H., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.009 · Cited by 2
“7 We were unable to identify published information on any glucose interference on urine biomarker assays of interest for the EMPA-KIDNEY trial, 8 so we aimed to assess whether alpha-1-microglobulin, measured using nephelometry; and dickkopf-3, epidermal growth factor, IL-18, kidney injury…”
Hsiao, L., Coca, S. G., Fantaye, S. H., Acosta, F. M., & Solis‐Herrera, C. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.003 · Cited by 2
Uster, A., Desai, N. R., Navaneethan, S. D., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.005 · Cited by 2
Modern Management of Chronic Kidney Disease in T2MD: A Practical Overview for Primary Care Providers
Girard, L. (2023) · Canadian Primary Care Today · doi:10.58931/cpct.2023.119 · Cited by 2
Kubica, J., Kubica, A., Grąbczewska, Z., Stróżecki, P., Adamski, P., Brymora, A., Donderski, R. Ł., Fabiszak, T., Flisiński, M., Gajda, R., et al. (2023) · Medical Research Journal · doi:10.5603/mrj.97187 · Cited by 2
Prise en charge médicamenteuse de la néphropathie diabétique
Bauduceau, B., Bordier, L., & Monnier, L. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.10.005 · Cited by 4
Sustainability and evolution of health care regarding treatments concerning type 2 diabetes mellitus
Ferrara, F., Zovi, A., Langella, R., Cavallaro, F., Nava, E., Trama, U., & Vitiello, A. (2023) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2023.100890 · Cited by 2
Inflammation in Diabetic Kidney Disease: Focus on New Therapeutic Considerations
Leehey, D. J., & Zhang, X. (2023) · Medical Research Archives · doi:10.18103/mra.v11i2.3614 · Cited by 3
SGLT 2 inhibitors: Searching for the best in class
Escobar, C., & Barrios, V. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.04.025 · Cited by 2
Treating chronic kidney disease to reduce cardiovascular risk
Cice, G., Monzo, L., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad067 · Cited by 2
Miñana, G., de la Espriella, R., Palau, P., Amiguet, M., Seller, J., Pinilla, J. M. G., Núñez, E., Górriz, J. L., Valle, A., Sanchís, J. M., et al. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.03.006 · Cited by 3
The macrocyclic lactone oxacyclododecindione reduces fibrosis progression
Saurin, S., Meineck, M., Rohr, M., Roth, W., Opatz, T., Erkel, G., Pautz, A., & Weinmann‐Menke, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1200164 · Cited by 3
“In particular, knowing that fibrosis is often triggered not only by mechanical effects but also by inflammatory processes, Oxa represents, for example, an option for a potentially even more efficient therapy compared to the SGLT-2 inhibitors currently newly approved for the slowing of progression in chronic renal fail…”
ResultLupusnephritis – von der Diagnose zur Therapie
Weinmann‐Menke, J. (2023) · rheuma plus · doi:10.1007/s12688-023-00666-z · Cited by 2
Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study
Tavares, C. A. M., Azevedo, L. C. P., Réa-Neto, Á., Campos, N. S., Amêndola, C. P., Bergo, R. R., Kozesinski-Nakatani, A. C., David-João, P. G., Westphal, G. A., Júnior, M. R. R. G., et al. (2023) · Critical Care Science · doi:10.5935/2965-2774.20230129-en · Cited by 3
The dapagliflozin in patients with myocardial infarction (DAPA-MI) trial in perspective
Rosselló, X., & Giménez, M. R. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad142 · Cited by 2
Yoon, Y., Kim, Y., Lee, S., Shin, B.-C., Kim, H.-L., Chung, J.-H., & Son, M. (2023) · Nutrients · doi:10.3390/nu15245039 · Cited by 2
A Prospective Study of Eplerenone in the Treatment of Patients with Glomerulonephritis
Papasotiriou, M., Georgopoulou, G. A., Bratsiakou, A., Ntrinias, T., Lyras, G., Goumenos, D. S., & Papachristou, E. C. (2023) · Biomedicines · doi:10.3390/biomedicines11123340 · Cited by 4
Yamada, T., Sugimoto, H., Hironaka, K., Morita, Y., Miura, H., Otowa‐Suematsu, N., Okada, Y., Hirota, Y., Sakaguchi, K., Kuroda, S., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae067 · Cited by 1
Real-Time Use of SGLT2i Verified in Pre-dialysis: The RSVP Cross-sectional Study
Wisbaum, A., Gaudreau, S., Cloutier, I., Robert, P., Kolment, R., Beauchesne, M.-F., & Couture, J. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241245995 · Cited by 2
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
Htoo, P. T., Najafzadeh, M., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Glynn, R. J., Schmedt, N., Déruaz‐Luyet, A., Koeneman, L., Paik, J. M., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0270 · Cited by 3
Neuen, B. L., Jun, M., Wick, J., Kotwal, S. S., Badve, S. V., Jardine, M., Gallagher, M., Chalmers, J. P., Nallaiah, K., Perkovic, V., et al. (2023) · medRxiv · doi:10.1101/2023.06.26.23291881 · Cited by 1
“6) 46 (35-70) 17 (13-27) A ll rhts resrved.”
Campos, M. A. J., Andújar, I., Keller, F., et al. (2023) · medRxiv · doi:10.1101/2023.08.01.23293501 · Cited by 2
Schork, A., Eberbach, M.-L., Bohnert, B. N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3343672/v1 · Cited by 2
Kronbichler, A., Anders, H., Frangou, E. A., Mirioğlu, Ş., Odler, B., Quintana, L. F., Soler, M. J., & Bruchfeld, A. N. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225563 · Cited by 2
SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
Sousa, M., Almeida, C., Marchão, N., Godinho, I., Lopes, J. A., & Gameiro, J. (2023) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2023.03.234 · Cited by 3
Usage des gliflozines dans la maladie rénale chronique
Hamdini, L., Defrance, F., Chetboun, M., Kerr-Conte, J. A., Frimat, M., Pattou, F. N., Vantyghem, M., Glowacki, F., & Maanaoui, M. (2023) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2023.04.014 · Cited by 6
Katholi, R. E., & Ervin Marcella, R. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132013 · Cited by 1
Making the Money Follow the Consensus in Nephrology Payment Reform
Baweja, M., & Vassalotti, J. A. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000179 · Cited by 1
SGLT2-Inhibitoren für Herz und Niere
van der Giet, M. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1971-3381 · Cited by 1
“Eine sehr lesenswerte Zusammenfassung wurde vom Cardio-Renal Trialists' Consortium 2022 publiziert [10].”
BackgroundRajasekaran, A., Larkina, M., Julian, B. A., Canetta, P. A., Roehm, B. A., Khalid, M., Mariani, L. H., & Rizk, D. V. (2023) · Kidney360 · doi:10.34067/kid.0000000000000306 · Cited by 1
Diabetic Kidney Disease: Increasing Hope with Transformative Therapies
Rosas, S. E., & Nasser, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-42045-0_4 · Cited by 1
Lessons learned from early-stage clinical trials for diabetic nephropathy
Rendell, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326025 · Cited by 1
Khoshnazar, S. M., Dehghani, A., Bagheri, F., Pezeshki, S., & Yousefzadeh, G. (2024) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2023.10.004 · Cited by 1
Rodwell, G. E. L., Ioannidis, J. P. A., & Kim, S. K. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1799312 · Cited by 2
Clinical trials and clinical trials networks
Neto, A. S., & Bellomo, R. (2024) · Respirology · doi:10.1111/resp.14704 · Cited by 1
Hypertension artérielle et insuffisance cardiaque
Saadi, M. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.03.006 · Cited by 2
Sakaguchi, E., Naruse, H., Ishihara, Y., Hattori, H., Yamada, A., Kawai, H., Muramatsu, T., Kitagawa, F., Takahashi, H., Ishii, J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32452 · Cited by 1
“Recent research has highlighted the potential of SGLT2 inhibitors in reducing the risk of kidney disease progression in patients with CKD [51,52] and type 2 diabetes [53].”
BackgroundDoes Our Classification System for CKD Serve the US Population Well?
Kattah, A. G., & Rule, A. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000433 · Cited by 1
Choe, H. J., Ko, Y.-H., Moon, S. J., et al. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1965 · Cited by 1
Neuen, B. L., & Solomon, S. D. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.002 · Cited by 2
Asser, P., Fischer, K., Ainla, T., Marandi, T., Blöndal, M., Saar, A., & Eha, J. (2024) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2024.2395875 · Cited by 2
“Studies such as the DAPA-CKD trial [27] and EMPA-KIDNEY trial [28] have highlighted the effectiveness of SGLT2 antagonists in mitigating the risk of kidney failure and cardiovascular events in CKD patients, presenting potential benefits for both individuals with DM and those without.”
The role of finerenone in the management of CKD in T2D –Practical considerations for primary care
Kanumilli, N., Miszon, M., Schnell, O., & Groop, P. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.001 · Cited by 3
Evidence of clinical trials of cardiac outcomes on renal disease
Vargas, V. M., Menon, T., Castro, M., & Vijayaraghavan, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00028-0 · Cited by 2
AlSahow, A., Alyousef, A., AlSabti, N., Alhelal, B. A., AlRajab, H., Alqallaf, A. K. E. A., Bahbahani, Y., Alkandari, A., Mazroue, A., dewidar, N., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03794-6 · Cited by 2
Taha, H., Momtaz, M., Elamragy, A. A., Younis, O., & Fahim, M. A. S. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10453-3 · Cited by 3
Groyer, H., Supiot, R., Tardu, J., Virely, N., Sivignon, M., San, D., Lévy, P., Ustyugova, A., & Massy, Z. A. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01398-4 · Cited by 2
Prediabetes and CKD: Does a causal relationship exist
Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.005 · Cited by 8
Harrison, L. L., Fu, E. L., Thomson, P. C., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae345 · Cited by 1
“Pharmacological strategies offering proven benefit include blood pressure control [1 , 2 ], renin–angiotensin– aldosterone system inhibition [3 , 4 ] and, more recently, treat-ment with finerenone [5 ] and sodium-glucose cotransporter 2 inhibitors [6 , 7 ].”
Ruebner, R. L., & Menon, S. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06606-z · Cited by 1
IgA vasculitis with nephritis accompanied by pulmonary tuberculosis: a case report
Abe, E., Kobayashi, R., Matsuoka, R., et al. (2025) · CEN Case Reports · doi:10.1007/s13730-025-00966-7 · Cited by 1
“SGLT2i have recently been shown to have renal protective effects regardless of the presence of diabetes [25, 26].”
Can we slow down the decline in renal function?
Cice, G., & Calò, L. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae123 · Cited by 1
Recurrent Focal Segmental Glomerulosclerosis Post Renal Transplantation
Díaz, M. A. T., Ballesteros, D. A., Covarrubias, O. L., Rojas, A. V. N., & Salazar, I. D. R. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1006530 · Cited by 1
Hong, D., Hong, M., Kim, O., Shin, H.-Y., Bak, M., Kim, D., Kim, J., Choi, K. H., Kim, E. K., Lee, J. M., et al. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.02.007 · Cited by 3
Pharmacokinetic Properties of Dapagliflozin in Patients with Stage 4 Chronic Kidney Disease
Li, D., Xie, D., Gu, A., Yang, Y., Guo, Z., Huang, X., Li, J., Wang, J., Zhang, L., Hu, B., et al. (2025) · American Journal of Nephrology · doi:10.1159/000544936 · Cited by 2
Treatment of immunoglobulin A nephropathy: Current perspective and future prospects
Şener, Y. Z., & Şener, S. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i19.101196 · Cited by 1
Abschätzung des Progressionsrisikos zum Nierenversagen
Chenot, J., Negnal, M., Tornow, C., Stracke, S., & Kiel, S. (2025) · Zeitschrift für Allgemeinmedizin · doi:10.1007/s44266-025-00354-5 · Cited by 1
Sahay, M., Prakash, S., Kataruka, M., Shah, H., Anthuvan, T., Gadia, S., Prasad, A., & Gupta, A. K. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_200_24 · Cited by 1
Skalsky, K., Romi, M., Shiyovich, A., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12040133 · Cited by 1
Barber, T., Neumiller, J. J., Fravel, M. A., Page, R. L., II, & Tuttle, K. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf045 · Cited by 2
Tratamiento actual de la enfermedad renal crónica
Salvador-González, B., Guerrero, S. C., Romano, J., Lumillo‐Gutiérrez, I., & Gonzalo, E. L. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.08.004 · Cited by 1
Brož, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.026 · Cited by 1
Shen, Z., & Ou, H. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70090 · Cited by 1
“This discrepancy may be attributable to increased recognition of the renal-protective effects of SGLT2is and GLP-1 RAs despite their lower glycemic ef fi cacy, as indicated in the literature 9,10,33 .”
Effects of sodium-glucose cotransporter 2 inhibitors on cardiomyopathy: a meta-analysis
Xu, B., Zhang, T., & Zhou, J. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02625-1 · Cited by 1
Role of Dapagliflozin versus Empagliflozin as add-on Therapy on Diabetic Nephropathy
Najim, H. D., Mohammed, M. M., & Rahmah, A. M. (2025) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.10.4.2410 · Cited by 1
Sue, Y., Lu, D.-E., Chang, T.-I., Chen, C.-Y., Chen, C., Hsu, S., Chu, Y.-L., Huang, N.-J., Chen, T.-H., Lin, F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124287 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Garofolo, M., Penno, G., Solini, A., Orsi, E., Vitale, M., Resi, V., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70061 · Cited by 2
“…slope but not the primary outcome (kidney disease progression and cardiovascular death) and other kidney secondary outcomes (kidney disease progression and total eGFR slope) in the normoalbuminuric group, likely due to the small number of events [29], suggests the need for trials of long duration.”
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus
Sethi, B. K., Chowdhury, S., Jain, S. M., Zargar, A. H., Chadha, M. D., Bhattacharyya, A., Shaikh, S. S., Makkar, B. M., Chawla, M. S., Kalra, P., et al. (2025) · Cureus · doi:10.7759/cureus.87002 · Cited by 1
“According to the EMPA-KIDNEY trial [95], in individuals with CKD, the primary outcomes (onset of ESKD, decrease in eGFR ( 10 mL/minute/1.73 m²), decrease in eGFR of at least 40% from baseline, or death from renal causes) occurred in 13% of individuals on empagliflozin.”
InfluentialWright, E. E., Cuenca, A. M. C., & Ngui, D. (2025) · Clinical Diabetes · doi:10.2337/cd25-0013 · Cited by 2
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Panagiotides, N. G., Weidenhammer, A., Prausmüller, S., Stadler, M., Spinka, G., Heitzinger, G., Arfsten, H., Strunk, G., Bartko, P. E., Goliasch, G., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13081846 · Cited by 1
Arae, H., Hoshino, S., Moromi, N., et al. (2025) · CEN Case Reports · doi:10.1007/s13730-025-01024-y · Cited by 1
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to mitigate renal function decline in both nondiabetic and diabetic CKD [3, 4], but their utility in patients with HIV-related or ART-induced kidney impairment remains unexplored.”
Wada, M., Mizuno, Y., Kajiyama, A., et al. (2025) · Cureus · doi:10.7759/cureus.89954 · Cited by 1
“In recent years, SGLT2 inhibitors have been used not only as therapeutic agents for diabetes mellitus but have also expanded their indications to include chronic kidney disease [21,22] and heart failure [23,24].”
Li, S. Y., Cui, S., Nan, Q. Y., Lin, X. J., Zheng, H. L., Piao, S. G., Jin, J. Z., Chung, B. H., Yang, C. W., Wang, L., et al. (2025) · Science Progress · doi:10.1177/00368504251358106 · Cited by 1
2024 Taiwan clinical practice guideline for diabetic kidney disease – an executive summary
Su, S., Chang, T.-C., Chiu, Y., Chu, C., Hsu, Y., Kuo, C., Lee, C., Lin, M., Lin, C., Lin, Y.-F., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.08.020 · Cited by 3
The importance of patient engagement when promoting age-inclusive research
Roberts, L. E., Burton, J. O., Sinha, M. D., Barratt, J., & Oni, L. (2025) · Research Involvement and Engagement · doi:10.1186/s40900-025-00780-6 · Cited by 1
“These drugs have been extensively tested in adult populations and have been shown to both slow the progression of CKD and reduce cardiovascular events [6, 7].”
Lee, Y., Nguyen, F., Anvari, S., Molnar, A. O., Doumouras, A. G., Walsh, M. W., & Hong, D. (2025) · British journal of surgery · doi:10.1093/bjs/znaf168 · Cited by 2
Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes
Kyriakidou, A., Koufakis, T., Gika, H., & Kotsa, K. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497906 · Cited by 13
“1,3,4 17 The fact that the cardiorenal benefit of SGLT-2 inhibitors emerges very early during the course of treatment and is observed independently of glycemic control and baseline glycated hemoglobin A 1c (HbA 1c ) values indicates that these drugs act through pleiotropic mechanisms.”
Shaker, A. M., Rakha, N. K., Keshk, A. A. M., & Din, U. A. S. E. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02757-x · Cited by 2
CHENG, A. Y. Y., Mottl, A. K., & MAGWIRE, M. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01796-7 · Cited by 5
“It is noteworthy that the SGLT2is used in the clinical trials were not required to be stopped if kidney function dropped to less than the eGFR inclusion criterion [64–66].”
Ko, H. Y., Hong, B., Bea, S., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112921 · Cited by 2
Elshehawy, M., Abdelgawad, A. A., Mohammed, E., Baig, M. Y., Morrissey, H., & Ball, P. (2025) · Journal of CardioRenal Medicine · doi:10.3390/jcrm1010002 · Cited by 3
“Longitudinal studies demonstrate that regression of LVH post-transplant is consistently observed, but the degree to which this translates into improved long-term survival remains de-bated [19,65].”
Ksiazek, S. H., Windpessl, M., Zitt, E., Rudnicki, M., Eller, K., Schwarz, C., Antlanger, M., Schmaldienst, S., Cejka, D., Oberbauer, R. W., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02590-y · Cited by 3
Yen, C., Fan, P., Lee, C., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000846 · Cited by 1
Recent Advances and Future Trends of[18F]-Labeled PET Agents for Renal Imaging
Higuchi, T., Chen, X., Siegmund, S. C., Klimek, K., Groener, D., Rowe, S. P., Fischereder, M., & Werner, R. A. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.09.008 · Cited by 2
Kao, Y., Chao, T., Cheng, Y., Chen, S., & Chan, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111370 · Cited by 1
Chronic kidney disease for the primary care provider
Doak, W., Lerma, E. V., & Shah, A. D. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.102027 · Cited by 2
Therapeutic strategy for diabetic patients with cardiovascular-kidney-metabolic syndrome
Huang, J., Zuo, P.-Y., Zhang, C., & Yan, J. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf180 · Cited by 1
How should we best manage the consequences of nephron loss in IgAN?
Kim, J., Kamal, F., Yeung, B., & Lafayette, R. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf225 · Cited by 1
Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD
Kosugi, T., Eriguchi, M., Tamaki, H., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000870 · Cited by 1
Mind the Gap Between Estimated Needs and Current Resources in Chronic Kidney Disease
Martino, F. K., & Nalesso, F. (2025) · Healthcare · doi:10.3390/healthcare13222826 · Cited by 1
Almalki, A. (2025) · Cureus · doi:10.7759/cureus.96931 · Cited by 4
Zhao, K., Zhu, H., Zheng, L., Wang, W., Liu, P., Yu, R., & Ma, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1690036 · Cited by 2
The influence of dapagliflozin on diabetic ocular complications: An observational cohort study
Chen, J.-H., Hung, F.-H., Wang, Y., Chen, J., Liao, S.-F., Hsueh, C.-M., Yeh, J., & Lip, G. Y. H. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107382 · Cited by 1
Murthy, L. S., Jain, A., Katakam, L., et al. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01596-6 · Cited by 1
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.